Pharmacyclics ( PCYC)

Drug: PCI-32765

Abstract No. 8012

Indication: non-Hodgkin's lymphoma

Clinical Trial: Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.

Presentation Time: Saturday, June 5. Oral session.

Notes: Since December, Pharmacyclics shares have gone from $2 to $7 as the company puts a history of drug development failures behind it and builds a new research pipeline.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today